Nootropics Index - Save on smarter supplements
Nootropics>Synthetic nootropics & research compounds>Nooglutyl
Synthetic nootropics & research compounds

Nooglutyl

Nooglutyl (Nooglutil; N-(5-hydroxynicotinoyl)-L-glutamic acid)

Nooglutyl (Nooglutil, ONK-10) is a synthetic glutamic-acid derivative studied in laboratory and animal research. Human studies of the related calcium-salt medicine Ampasse used intravenous administration in patients, not oral powder in healthy adults. Compare the exact chemical form and route before interpreting claims, doses or prices.

GlutamatergicSyntheticMostly Animal EvidenceInsufficient EvidenceForm Dependent EvidenceLong Term Safety Unknown
Updated October 2026/5 min read/6 citations
Reviewed by the NootropicsIndex editorial team.Method: prioritize cited human research and official safety or regulatory sources; compare retailer-listed prices without endorsing products.Affiliate disclosure
01

What is it?

What the evidence applies to

4

This profile concerns Nooglutyl free acid, also called Nooglutil or ONK-10. Published human research on Ampasse concerns a related calcium salt given intravenously. Form, route and population are essential when deciding whether a study applies to a powder listing.

Human trials exist, but not for an oral powder protocol4
A 2019 placebo-controlled trial involved 80 patients aged 50-75 using intravenous Ampasse calcium salt. Its patient population and route differ from oral free-acid use by healthy adults. It should not be cited as validation of a retail powder dose.

A later clinical study has the same applicability limit

5

A 2021 placebo-controlled study enrolled 124 patients with chronic cerebrovascular disorders and reported better cognitive test results with intravenous Ampasse. Adverse events occurred in 14.52% versus 8.06% with placebo; the difference was not statistically significant. This short patient trial does not establish long-term oral safety.

Oral dosage cannot be inferred from injected doses4
No controlled oral free-acid dosing study was identified in this review. The intravenous calcium-salt trial protocol is not an oral conversion guide. Retail serving suggestions and animal doses cannot establish an effective or safe oral amount.
02

Names, aliases and forms

Common NameNooglutyl
Spelling VariantNooglutil
Chemical NameN-(5-hydroxynicotinoyl)-L-glutamic acid
Iupac Name(2S)-2-[(5-hydroxypyridine-3-carbonyl)amino]pentanedioic acid
Cas Number112193-35-8
Research CodeONK-10
Pubchem Cid147523
InchikeyXFZGYOJFPGPYCS-QMMMGPOBSA-N
03

Mechanisms of action

What AMPA binding means

2

AMPA receptors are part of glutamate signalling in the brain. Nooglutil competed for AMPA receptor binding sites in rat-brain laboratory assays. Binding is a mechanistic observation, not proof of a cognitive benefit or predictable effect in a person.

04

Potential effects and evidence map

Laboratory and animal findings underpin interest in Nooglutyl. Published patient trials concern intravenous Ampasse, a calcium salt, and cannot establish oral free-acid efficacy or safety in healthy adults. No controlled human oral study was identified in the sources reviewed on 18 October 2026.

Effect domainMagnitudeGrade
Memory / learning5
UnknownConfidence: Low

A cognitive benefit from oral Nooglutyl free acid in healthy adults has not been established. The cited patient study used intravenous Ampasse.

Note Zero indicates no established benefit in this use context, not proof of no effect. The cited clinical trial cannot establish an oral free-acid effect magnitude.

0/5
E
05

Timing & effect horizon

Effect horizonUnknown
Unknown
Why a four-hour half-life claim is misleading3

The often-cited four-hour human The time for blood levels to fall by half during the final elimination phase.Source came from mathematical extrapolation of injected calcium-salt data in rats and rabbits. It was not a measured human oral half-life. Oral onset, effect duration and a supported cycle remain unestablished by these sources.

06

Safety, side effects and risk profile

Oral safety remains uncharacterized5
Risk is unknown for oral free-acid use: an established healthy-adult dose and duration are missing. This does not mean low risk or demonstrated severe harm. Short intravenous patient studies cannot settle long-term oral effects, pregnancy or lactation safety, or medication and supplement interactions.
07

Legal and regulatory status

A US registry identifier is not approval6

As of 18 October 2026, the US FDA substance registry lists Nooglutyl under UNII 09UM5JOS3W. FDA explicitly states that a UNII does not imply regulatory review or approval. This identifier is not proof of US supplement eligibility or permission to import; other jurisdictions require separate assessment.

08

How it compares

Nooglutyl and Noopept are distinct2

Nooglutyl is N-(5-hydroxynicotinoyl)-L-glutamic acid. Noopept is a different compound; a laboratory paper tested them separately. A similar name does not justify borrowing claims or dosing instructions.

09

Practical buying and quality notes

  • Match Nooglutyl or Nooglutil to CAS 112193-35-8 and PubChem CID 147523. Ask whether the material is the free acid or a salt. Price comparisons across different chemical identities, including Noopept or 7,8-DHF, do not describe interchangeable products.1
  • For a listing under consideration, check the batch number, laboratory identity report and purity method. A purity percentage alone does not establish human safety. Compare cost per gram only after matching chemical form and package mass; include shipping and distinguish powder from capsules.1
10

FAQ

What is an evidence-based oral Nooglutyl dose?

4

The reviewed sources do not establish one. Clinical Ampasse reports concern intravenous calcium salt in patients, so their amounts cannot validate oral free-acid serving suggestions.

How long does Nooglutyl last, and should it be cycled?

3

Human oral onset and effect duration were not established in the sources reviewed. The animal-based half-life extrapolation is not an effect-duration measurement, and it does not support a cycle or dosing interval.

Does a study of Ampasse validate Nooglutyl powder?

5

No direct validation follows. A related chemical form given intravenously to patients has different evidence applicability from an oral free-acid product used by a healthy adult.

11

References

  1. PubChem. Nooglutil. Compound CID 147523.
  2. Firstova IuIu, Vasil’eva EV, Kovalev GI. Studying specific effects of nootropic drugs on glutamate receptors in the rat brain. Eksp Klin Farmakol. 2011;74(1):6-10.
  3. Firsov AA et al. Pharmacokinetics of n-(5-oxynicotinoyl)-L-glutamic acid calcium salt upon bolus administration in rats and rabbits: interspecies extrapolation. Eksp Klin Farmakol. 2010;73(12):31-35.
  4. Kiselev AV et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of ampasse in chronic cerebral ischemia. Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(4):21-25.
  5. Skoromets AA et al. Efficacy and safety of ampasse: randomized, double-blind, placebo-controlled trial in patients with chronic cerebrovascular disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2021;121(5):26-32.
  6. US FDA Substance Registration System. Nooglutyl, UNII 09UM5JOS3W.
Note

This page is informational and summarizes available evidence. It is not medical advice, a recommendation, or a substitute for guidance from a qualified clinician.